Between 14 and 16 hours after administration of sodium polystyrene sulfonate, researchers observed a median serum potassium decrease of 0.8 mEq/L after a 30-gram dose and a median decrease of 0.7 ...

Among 63,323 patients on hemodialysis (HD) from the 2002 to 2018 Dialysis Outcomes and Practice Patterns Study (DOPPS), 7107 (11.2%) received the potassium binder SPS.

After that, another option is to take a potassium-binding agent, either patiromer (Veltassa), sodium polystyrene sulfonate (Kayexalate), or sodium zirconium cyclosilicate (Lokelma).

Despite treatment with sodium polystyrene sulfonate (SPS), patients hospitalized with hyperkalemia have a high burden of readmissions and hyperkalemia recurrence, according to new research ...

Lokelma, patiromer (Veltassa) and sodium polystyrene sulfonate (Kayexalate*) are all used to lower potassium levels, and they belong to the same group of drugs.

Patiromer (Veltassa), sodium zirconium cyclosilicate (Lokelma) and sodium polystyrene sulfonate (a discontinued brand name was called Kayexalate) all are substances that avidly bind potassium ...

Unlike sodium polystyrene sulfonate, ZS-9 is an inorganic exchanger that preferentially entraps monovalent cations, specifically excess potassium ions, over divalent cations in the ...

Similar to Lokelma, Kayexalate (sodium polystyrene sulfonate) was a drug prescribed to treat hyperkalemia (high potassium levels). The brand-name drug Kayexalate is no longer available.

Dr. Hershberger answers the question: 'Spironolactone Effects On Potassium?' — -- Question: What effects does spironolactone have on my blood potassium and should I be monitored while on it ...

Results of blood cultures were negative, and with dialysis, the patient’s serum potassium level decreased to 4.8 mEq/L. The platelet count increased to 619×103/µL and peaked at 911×103/µL.